News Release

PURMX Enters into Capital Alliance with Nippon Shokubai Co., Ltd. and Initiates Research to Validate the Potential of Fol-Dab8–microRNA Complexes

PURMX Therapeutics, Inc. (Headquartered in Hiroshima, Japan; President and CEO: Hidetoshi Tahara) is pleased to announce that it has initiated research to validate the potential of complexes comprising microRNA and Fol-Dab8, a drug delivery system (DDS) based on a cationic peptide developed by Nippon Shokubai Co., Ltd. (Headquartered in Osaka, Japan; President & CEO: Kazuhiro Noda; hereinafter “Nippon Shokubai”) that selectively delivers nucleic acids by targeting folate rece

Sep 29

PURMX Enters into Capital Alliance with FRONTEO, Inc. and Launches PoC for AI-Driven microRNA Drug Discovery

PURMX Therapeutics, Inc.（Headquartered in Hiroshima, Japan; President and CEO: Hidetoshi Tahara）is pleased to announce that we have commenced a proof of concept (PoC) to identify target molecules and elucidate the mechanism of action of our naturally occurring microRNA-based nucleic acid therapeutics by leveraging “Drug Discovery AI Factory” (hereinafter “DDAIF”), an AI-based drug discovery support service provided by FRONTEO, Inc. (Headquartered in Tokyo, Japan; President &

Aug 13

"MIRX002" Achieves Primary Endpoint in Phase I Clinical Trial for Malignant Pleural Mesothelioma

PURMX Therapeutics, Inc. (Headquartered in Hiroshima, Japan; President and CEO: Hidetoshi Tahara; hereinafter "the Company") is pleased to announce the completion of both the Single Ascending Dose (SAD) study (Protocol No.: MIRX002-01) and the Multiple Ascending Dose (MAD) study (Protocol No.: MIRX002-02), investigator-initiated clinical trials for malignant pleural mesothelioma using natural-type microRNA replacement therapy, for which the Company supplied the investigationa

May 27